Search

Your search keyword '"Shimoji, Kiyofumi"' showing total 9 results
Start Over Author "Shimoji, Kiyofumi"
9 results on '"Shimoji, Kiyofumi"'

2. MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers

Author

Shimoji, Kiyofumi, primary, Masuda, Takeshi, additional, Yamaguchi, Kakuhiro, additional, Sakamoto, Shinjiro, additional, Horimasu, Yasushi, additional, Nakashima, Taku, additional, Miyamoto, Shintaro, additional, Iwamoto, Hiroshi, additional, Fujitaka, Kazunori, additional, Hamada, Hironobu, additional, Takeno, Sachio, additional, Hide, Michihiro, additional, Teishima, Jun, additional, Ohdan, Hideki, additional, and Hattori, Noboru, additional

Published
2021
Full Text
View/download PDF

3. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone

Author

MASUDA, TAKESHI, primary, WAKABAYASHI, YU, additional, NAKASHIMA, TAKU, additional, NISHIMURA, YOSHIFUMI, additional, SHIMOJI, KIYOFUMI, additional, YAMAGUCHI, KAKUHIRO, additional, SAKAMOTO, SHINJIRO, additional, HORIMASU, YASUSHI, additional, MIYAMOTO, SHINTARO, additional, SENOO, TADASHI, additional, IWAMOTO, HIROSHI, additional, OHSHIMO, SHINICHIRO, additional, FUJITAKA, KAZUNORI, additional, HAMADA, HIRONOBU, additional, and HATTORI, NOBORU, additional

Published
2021
Full Text
View/download PDF

4. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers

Author

Shimoji, Kiyofumi, primary, Masuda, Takeshi, additional, Yamaguchi, Kakuhiro, additional, Sakamoto, Shinjiro, additional, Horimasu, Yasushi, additional, Nakashima, Taku, additional, Miyamoto, Shintaro, additional, Iwamoto, Hiroshi, additional, Fujitaka, Kazunori, additional, Hamada, Hironobu, additional, Takeno, Sachio, additional, Hide, Michihiro, additional, Teishima, Jun, additional, Ohdan, Hideki, additional, and Hattori, Noboru, additional

Published
2020
Full Text
View/download PDF

5. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non‐small cell lung cancer

Author

Wakabayashi, Yu, primary, Masuda, Takeshi, additional, Fujitaka, Kazunori, additional, Nakashima, Taku, additional, Okumoto, Joe, additional, Shimoji, Kiyofumi, additional, Nishimura, Yoshifumi, additional, Yamaguchi, Kakuhiro, additional, Sakamoto, Shinjiro, additional, Horimasu, Yasushi, additional, Miyamoto, Shintaro, additional, Iwamoto, Hiroshi, additional, Ohshimo, Shinichiro, additional, Hamada, Hironobu, additional, and Hattori, Noboru, additional

Published
2020
Full Text
View/download PDF

6. EGFR gene mutation is not a significant prognostic factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone.

Author

Masuda, Takeshi, primary, Wakabayashi, Yu, additional, Shimoji, Kiyofumi, additional, Yamaguchi, Kakuhiro, additional, Sakamoto, Shinjiro, additional, Nishimura, Yoshihumi, additional, Horimasu, Yasushi, additional, Nakashima, Taku, additional, Miyamoto, Shintaro, additional, Senoo, Tadashi, additional, Iwamoto, Hiroshi, additional, Ohshimo, Shinichiro, additional, Fujitaka, Kazunori, additional, Hamada, Hironobu, additional, and Hattori, Noboru, additional

Published
2020
Full Text
View/download PDF

7. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers.

Author

Shimoji, Kiyofumi, primary, Masuda, Takeshi, additional, Nakanishi, Yu, additional, Yamaguchi, Kakuhiro, additional, Sakamoto, Shinjiro, additional, Horimasu, Yasushi, additional, Nakashima, Taku, additional, Miyamoto, Shintaro, additional, Iwamoto, Hiroshi, additional, Fujitaka, Kazunori, additional, Hamada, Hironobu, additional, and Hattori, Noboru, additional

Published
2020
Full Text
View/download PDF

9. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non‐small cell lung cancer.

Author

Wakabayashi, Yu, Masuda, Takeshi, Fujitaka, Kazunori, Nakashima, Taku, Okumoto, Joe, Shimoji, Kiyofumi, Nishimura, Yoshifumi, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Miyamoto, Shintaro, Iwamoto, Hiroshi, Ohshimo, Shinichiro, Hamada, Hironobu, and Hattori, Noboru

Abstract

The standard treatment for locally advanced non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by anti‐programmed cell death‐ligand 1 (anti‐PD‐L1) treatment. BIM deletion polymorphism induces the suppression of apoptosis resulting from epidermal growth factor (EGFR)‐tyrosine kinase inhibitors in EGFR‐mutated NSCLC patients. We aimed to examine the effects of BIM polymorphism on CRT and anti‐PD‐L1/PD‐1 treatment in NSCLC patients. In this retrospective study of 1312 patients with unresectable NSCLC treated at Higashi‐Hiroshima Medical Center and Hiroshima University Hospital between April 1994 and October 2019, we enrolled those who underwent CRT or chemotherapy using carboplatin + paclitaxel or cisplatin + vinorelbine, or anti‐PD‐L1/PD‐1 treatment. Of 1312 patients, 88, 80, and 74 underwent CRT, chemotherapy, and anti‐PD‐L1/PD‐1 treatment, respectively, and 17.0%, 15.2% and 17.6% of these patients showed BIM polymorphism. Among patients receiving CRT, the progression‐free survival was significantly shorter in those with BIM deletion than in those without. In the multivariate analyses, BIM polymorphism was an independent factor of poor anti‐tumor effects. These results were not observed in the chemotherapy and anti‐PD‐L1/PD‐1 treatment groups. In in vitro experiments, BIM expression suppression using small interfering RNA in NSCLC cell lines showed a significantly suppressed anti‐tumor effect and apoptosis after irradiation but not chemotherapy. In conclusion, we showed that BIM polymorphism was a poor‐predictive factor for anti‐tumor effects in NSCLC patients who underwent CRT, specifically radiotherapy. In the implementation of CRT in patients with BIM polymorphism, we should consider subsequent treatment, keeping in mind that CRT may be insufficient. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results